Gynae BT 2017

Pooled randomised NSGO-EORTC/Iliade trials Radiotherapy vs RT plus platinum-based chemotherapy x4

Overall survival

Progression free survival

Serous and clear cell cancers in NSGO/EORTC trial (33%)

OS 75 vs 82%, p=0.07

PFS 69 vs 78%, p=0.009

Hogberg et al, EJC 2010